Active Surveillance

What is Active Surveillance?

  • Involves close monitoring of small, slow-growing prostate cancer with relatively normal-looking cells (as determined by your biopsy results);
  • May be appropriate if you are an older man who may be more likely to develop other (age-related) conditions that may have a greater impact on your health;
  • Doesn’t involve invasive procedures
  • Doesn’t involve drugs
  • No side effects
Your prostate cancer will be monitored closely and may involve the following procedures:
 
  • Regular PSA tests and digital rectal exams
  • Monitoring PSA doubling time (this may mean having a PSA test done every 3-6 months)
    • PSA doubling time refers to how long it takes for a man’s level of prostate-specific antigen to double
  • Occasional repeat biopsies
  • Follow-up bone scan and/or CT scan to monitor disease progression
You will be offered more aggressive treatment at the first sign your prostate cancer has progressed or tumour has grown. Your doctor will discuss the advantages and disadvantages of each treatment option.  You should know that active surveillance is not a cure for prostate cancer.  It also carries the risk that your prostate cancer might spread (metastasize).  This is why regular monitoring is so important. 

You may have heard of the term “watchful waiting”.  Watchful waiting involves having no treatment for your prostate cancer.  Rather than treating the prostate cancer, your doctor will wait until you start having symptoms and treat those, usually with medication. The goal of watchful waiting is not to cure your prostate cancer, but treat your symptoms to make you feel better.
 

For more information and support:





Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

(TORONTO, Canada - Aug 7, 2017) -- Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50% of patient tumour samples.
More

Movember Foundation and Prostate Cancer Canada team up to turn research into results

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
More

Plaid for Dad participation skyrockets in third year

July 7, 2017 - TORONTO, ON - Launched for the first time in 2015, Prostate Cancer Canada's (PCC) Plaid for Dad campaign has further established itself as the way Canadians are choosing to give back on Father's Day weekend.
More


Click here for news archive